Engineering biomimetic materials for islet transplantation

Current Diabetes Reviews

Volumn 11, Issue 3, 2015, Pages 163-169

  Yang, Ethan Y ^a,b   Kronenfeld, Joshua P ^a,b   Stabler, Cherie L ^a,b,c,d  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Miami College of Engineering   (United States)

^d J Crayton Pruitt Family Department of Biomedical Engineering   (United States)

Author keywords

Anoikis; Biomaterials; Diabetes; Encapsulation; Immunomodulation; Inflammation; Scaffolds

Indexed keywords

BIOMIMETIC MATERIAL; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; ANOIKIS; ANTIGEN PRESENTATION; ARTICLE; BASEMENT MEMBRANE; BIOENGINEERING; CELL DEATH; CELL INTERACTION; CELL SURVIVAL; COMPLEMENT ACTIVATION; ENGRAFTMENT; EXTRACELLULAR MATRIX; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INFLAMMATION; MICROENVIRONMENT; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVASCULARIZATION; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; PROCEDURES; TISSUE SCAFFOLD;

ADAPTIVE IMMUNITY; ANOIKIS; BIOENGINEERING; BIOMIMETIC MATERIALS; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; ISLETS OF LANGERHANS TRANSPLANTATION; TISSUE SCAFFOLDS;

EID: 84931824859     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811666150317130440     Document Type: Article

References (82)

1. Raff H. Medical Physiology: A Systems Approach. New York: McGraw Hill; 2001.
2. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311(17): 1778-86.
3. Andreoli TE. Cecil Essentials of Medicine. 6th ed: W.B. Saunders Co.; 2003.
4. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation: Strategic opportunities in clinical islet transplantation. Diabetes 2005; 54(7): 2060-9.
5. Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diab Metab Synd Obesity: Targ Ther 2014; 7: 211-23.
6. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002; 51(1): 66-72.
7. Eich T, Eriksson O, Sundin A, et al. Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation 2007; 84(7): 893-8.
8. Stendahl JC, Kaufman DB, Stupp SI. Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. Cell transplantation 2009; 18(1): 1-12.
9. Korpos E, Kadri N, Kappelhoff R, et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes 2013; 62(2): 531-42.
10. Kraemer M. Henochs purpura; a case with bullous skin lesions and residual scars, roentgenologic considerations. Gastroenterology 1947; 9(5): 608-11.
11. Lin CC, Raza A, Shih H. PEG hydrogels formed by thiol-ene photo-click chemistry and their effect on the formation and recov ery of insulin-secreting cell spheroids. Biomaterials. 2011; 32(36): 9685-95.
12. Zimmermann H, Zimmermann D, Reuss R, et al. Towards a medically approved technology for alginate-based microcapsules allowing long-term immunoisolated transplantation. J Mater Sci Mater Med 2005; 16(6): 491-501.
13. Orive G, Carcaboso A, Hermndez R, Gascn A, Pedraz J. Biocompatibility evaluation of different alginates and alginate-based microcapsules. Biomacromolecules 2005; 6(2): 927-31.
14. Lin CC, Anseth KS. Cell-cell communication mimicry with poly(ethylene glycol) hydrogels for enhancing beta-cell function. Proceedings of the National Academy of Sciences of the United States of America 2011; 108(16): 6380-5.
15. Konstantinova I, Nikolova G, Ohara-Imaizumi M, et al. EphAEphrin- A-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell 2007; 129(2): 359-70.
16. Weber LM, Anseth KS. Hydrogel encapsulation environments functionalized with extracellular matrix interactions increase islet insulin secretion. Matrix biology: journal of the International Society for Matrix Biology 2008; 27(8): 667-73.
17. Li W, Lee S, Ma M, et al. Microbead-based biomimetic synthetic neighbors enhance survival and function of rat pancreatic betacells. Scientific reports 2013; 3: 2863.
18. Kizilel S, Scavone A, Liu X, et al. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion. Tissue engineering Part A 2010; 16(7): 2217-28.
19. Salvay D, Rives C, Zhang X, et al. Extracellular matrix proteincoated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 2008; 85(10): 1456-64.
20. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48(2): 407-17.
21. Goh SK, Bertera S, Olsen P, et al. Perfusion-decellularized pancreas as a natural 3D scaffold for pancreatic tissue and whole organ engineering. Biomaterials 2013; 34(28): 6760-72.
22. Mirmalek-Sani SH, Orlando G, McQuilling JP, et al. Porcine pancreas extracellular matrix as a platform for endocrine pancreas bioengineering. Biomaterials 2013; 34(22): 5488-95.
23. Pileggi A, Molano RD, Ricordi C, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation 2006; 81(9): 1318-24.
24. Sakurai T, Satake A, Sumi S, et al. The efficient prevascularization induced by fibroblast growth factor 2 with a collagen-coated device improves the cell survival of a bioartificial pancreas. Pancreas 2004; 28(3): e70-9.
25. Stiegler P, Matzi V, Pierer E, et al. Creation of a prevascularized site for cell transplantation in rats. Xenotransplantation 2010; 17(5): 379-90.
26. Chow LW, Wang LJ, Kaufman DB, Stupp SI. Self-assembling nanostructures to deliver angiogenic factors to pancreatic islets. Biomaterials 2010; 31(24): 6154-61.
27. Salimath AS, Phelps EA, Boopathy AV, et al. Dual delivery of hepatocyte and vascular endothelial growth factors via a proteasedegradable hydrogel improves cardiac function in rats. PloS one 2012; 7(11): e50980.
28. Brady AC, Martino MM, Pedraza E, et al. Proangiogenic hydrogels within macroporous scaffolds enhance islet engraftment in an extrahepatic site. Tissue Eng Part A 2013; 19(23-24): 2544-52.
29. Ellis CE, Vulesevic B, Suuronen E, Yeung T, Seeberger K, Korbutt GS. Bioengineering a highly vascularized matrix for the ectopic transplantation of islets. Islets 2013; 5(5): 216-25.
30. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66(1): 221- 31.
31. Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cellular Biochem 2007; 101(1): 259-70.
32. Bowers DT, Chhabra P, Langman L, Botchwey EA, Brayman KL. FTY720-loaded poly(DL-lactide-co-glycolide) electrospun scaffold significantly increases microvessel density over 7 days in streptozotocin- induced diabetic C57b16/J mice: preliminary results. Transplant Proc 2011; 43(9): 3285-7.
33. Colton CK. Oxygen supply to encapsulated therapeutic cells. Adv Drug Del Rev 2014; 67-68: 93-110.
34. Pedraza E, Coronel MM, Fraker CA, Ricordi C, Stabler CL. Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating biomaterials. Proceed National Academy Sci United States of America 2012; 109(11): 4245- 50.
35. Barkai U, Weir GC, Colton CK, et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transpl 2013; 22(8): 1463-76.
36. Ludwig B, Rotem A, Schmid J, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proceed National Academy of Sci 2012; 109(13): 5022-7.
37. Ludwig B, Zimerman B, Steffen A, et al. A novel device for islet transplantation providing immune protection and oxygen supply. Horm Metab Res 2010; 42(13): 918-22.
38. Shimoda M, Chen S, Noguchi H, Matsumoto S, Grayburn PA. In vivo non-viral gene delivery of human vascular endothelial growth factor improves revascularisation and restoration of euglycaemia after human islet transplantation into mouse liver. Diabetologia 2010; 53(8): 1669-79.
39. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000; 105(2): 125- 33.
40. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukocyte Bio 2005; 77(5): 587-97.
41. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755-62.
42. Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B. Inflammatory response in islet transplantation. Int J Endocrinol 2014; 2014: 451035.
43. Xie D, Smyth CA, Eckstein C, Bilbao G, Mays J, Eckhoff DE, et al. Cytoprotection of PEG-modified adult porcine pancreatic islets for improved xenotransplantation. Biomaterials. 2005; 26(4): 403- 12.
44. Teramura Y, Iwata H. Surface modification of islets with PEGlipid for improvement of graft survival in intraportal transplantation. Transplantation 2009; 88(5): 624-30.
45. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007; 56(8): 2008-15.
46. Stabler CL, Sun XL, Cui W, Wilson JT, Haller CA, Chaikof EL. Surface re-engineering of pancreatic islets with recombinant azidothrombomodulin. Bioconjugate Chem 2007; 18(6): 1713-5.
47. Wilson J, Haller CA, Qu Z, Cui W, Urlam M, Chaikof EL. Biomolecular surface engineering of pancreatic islets with thrombomodulin. Acta Biomater. 2010; 6(6): 1895-903.
48. Cui W, Wilson JT, Wen J, et al. Thrombomodulin improves early outcomes after intraportal islet transplantation. Am J Transp: off J Am Society Transplant Am Society Transplant Surgeons 2009; 9(6): 1308-16.
49. Teramura Y, Iwata H. Improvement of graft survival by surface modification with poly(ethylene glycol)-lipid and urokinase in intraportal islet transplantation. Transplantation 2011; 91(3): 271-8.
50. Burke SJ, Lu D, Sparer TE, Karlstad MD, Collier JJ. Transcription of the gene encoding TNF-alpha is increased by IL-1beta in rat and human islets and beta-cell lines. Mol Immunol 2014; 62(1): 54-62.
51. Kuraya D, Watanabe M, Koshizuka Y, et al. Efficacy of DHMEQ, a NF-kappaB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage. Transplantation 2013; 96(5): 445-53.
52. Akash MS, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 2012; 101(5): 1647-58.
53. Su J, Hu BH, Lowe WL Jr, Kaufman DB, Messersmith PB. Antiinflammatory peptide-functionalized hydrogels for insulinsecreting cell encapsulation. Biomaterials 2010; 31(2): 308-14.
54. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid free immunosuppressive regimen. N Engl J Med 2000; 343(4): 230-8.
55. Kaplan B, West P, Neeley H, et al. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. Clin Transp 2008; 22(2): 250-3.
56. Chang TM. Semipermeable Microcapsules. Science 1964; 146(3643): 524-5.
57. Basta G, Montanucci P, Luca G, et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care 2011; 34(11): 2406-9.
58. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proceed National Academy Sci United States Am 2013; 110(47): 19054-8.
59. Tomei AA, Manzoli V, Fraker CA, et al. Device design and materials optimization of conformal coating for islets of Langerhans. Proceed National Academy Sci United States Am 2014; 111(29): 10514-9.
60. Krol S, del Guerra S, Grupillo M, Diaspro A, Gliozzi A, Marchetti P. Multilayer nanoencapsulation. New approach for immune protection of human pancreatic islets. Nano Letters 2006; 6(9): 1933- 9.
61. Tong W, Song X, Gao C. Layer-by-layer assembly of microcapsules and their biomedical applications. Chem Society Rev 2012; 41(18): 6103-24.
62. Rengifo HR, Giraldo JA, Labrada I, Stabler CL. Long-term survival of allograft murine islets coated via covalently stabilized polymers. Adv Healthcare Mat 2014; 3(7): 1061-70.
63. Rengifo H, Gattas-Asfura KM, Giraldo J, Stabler C. Fabrication of nano-scale coatings for islet encapsulation. Cell Medicine B 2011; 2011(2): Supp 1.
64. Shipova L, Kuprina NI, Rudinskaia TD. [Ontogeny of the mouse liver studied with hepatocyte membrane antigens and a comparison with alpha-fetoprotein synthesis]. Ontogenez 1988; 19(3): 264-9.
65. Sojka DK, Fowell DJ. Regulatory T cells inhibit acute IFN-gamma synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proceed National Academy Sci United States Am 2011; 108(45): 18336-41.
66. Tonkin DR, He J, Barbour G, Haskins K. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J Immunol 2008; 181(7): 4516-22.
67. Nagahama K, Nishimura E, Sakaguchi S. Induction of tolerance by adoptive transfer of Treg cells. Methods Mol Biol 2007; 380: 431- 42.
68. Cabello-Kindelan C, de la Barrera A, Malek TR, Bayer AL. In vivo environment necessary to support transplanted donor mouse T regulatory cells. Am J Transplant: official J Am Society Transplant Am Society Transplant Surgeons 2014; 14(5): 1032-45.
69. Pinto E, Zhang B, Song S, Bodor N, Buchwald P, Hochhaus G. Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant. Pharmazie 2010; 65(6): 429-35.
70. Buchwald P, Bocca N, Marzorati S, et al. Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation. Pharmazie 2010; 65(6): 421-8.
71. Jhunjhunwala S, Balmert SC, Raimondi G, et al. Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells. J Controlled Release: official J Contr Release Society 2012; 159(1): 78-84.
72. Gajanayake T, Olariu R, Leclere FM, et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. Sci Translational Med 2014; 6(249): 249ra110.
73. Yolcu ES, Zhao H, Bandura-Morgan L, et al. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J Immunol 2011; 187(11): 5901-9.
74. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997; 3(7): 738-43.
75. Takeuchi T, Ueki T, Nishimatsu H, et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999; 162(1): 518- 22.
76. O' Reilly L, Tai L, Lee L, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461(7264): 659-63.
77. Hume PS, He J, Haskins K, Anseth KS. Strategies to reduce dendritic cell activation through functional biomaterial design. Biomaterials 2012; 33(14): 3615-25.
78. Kheradmand T, Wang S, Gibly RF, et al. Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions. Biomaterials 2011; 32(20): 4517-24.
79. Getts DR, Martin AJ, McCarthy DP, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nature Biotech 2012; 30(12): 1217-24.
80. Hunter Z, McCarthy DP, Yap WT, et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS nano 2014; 8(3): 2148-60.
81. Kontos S, Kourtis IC, Dane KY, Hubbell JA. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proceed National Academy Sci United States America 2013; 110(1): E60-8.
82. Bryant J, Hlavaty KA, Zhang X, et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials 2014; 35(31): 8887-94.